Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2019
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021

Category: Retinal Vascular Disease

See more